• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

20.59 +0.26 (+1.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Zai Lab Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
May 11, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
May 07, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
April 22, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
April 18, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
April 17, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
April 01, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
March 17, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
February 26, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
February 10, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
January 13, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
January 06, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
December 23, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
December 08, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Updates to China’s National Reimbursement Drug List
December 07, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
November 06, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Participation in Investor Conferences in November and December 2025
October 31, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
October 24, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
October 15, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
October 13, 2025
From Zai Lab Limited
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB
September 06, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
September 01, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Participation in Investor Conferences in September 2025
August 28, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer
August 19, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Establishes Oncology Scientific Advisory Board
August 13, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates
August 07, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
July 10, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
June 30, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
June 13, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting
June 02, 2025
From Zai Lab Limited
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap